CRM
NTUS

Cramer Rosenthal McGlynn’s Natus Medical Inc NTUS Stock Holding History

Cramer Rosenthal McGlynn’s Portfolio NTUS Stock Details NTUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-501,431
Closed -$10.9M – 108
2020
Q2 		$10.9M Sell
501,431
-372,192
-43% -$8.52M 0.44% 71
2020
Q1 		$20.2M Sell
873,623
-510,361
-37% -$14.8M 0.95% 49
2019
Q4 		$45.7M Sell
1,383,984
-124,417
-8% -$3.99M 1.3% 25
2019
Q3 		$48M Sell
1,508,401
-26,595
-2% -$775K 1.36% 22
2019
Q2 		$39.4M Buy
1,534,996
+246,269
+19% +$6.28M 1.08% 34
2019
Q1 		$32.7M Buy
1,288,727
+516,486
+67% +$15.4M 0.78% 53
2018
Q4 		$26.3M Buy
+772,241
New +$25.1M 0.66% 66

Other funds holding NTUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cramer Rosenthal McGlynn's NTUS Position: Q3 2020 in Review

Cramer Rosenthal McGlynn sold out of Natus Medical Inc (NTUS) in Q3 2020, closing a stake of 501,431 shares — an estimated $10.9M sold.

Cramer Rosenthal McGlynn first reported a position in NTUS in Q4 2018 and held it in 7 quarters. The position peaked at $48M in Q3 2019. 159 funds tracked by Wall St. Rank hold NTUS as of Q3 2020.

  • Cramer Rosenthal McGlynn reported no remaining Natus Medical Inc position as of Q3 2020 after selling out during the quarter.
  • Cramer Rosenthal McGlynn sold 501,431 Natus Medical Inc shares in Q3 2020, an estimated $10.9M.
  • Cramer Rosenthal McGlynn first reported a position in Natus Medical Inc in Q4 2018 and held it in 7 quarters.
  • Cramer Rosenthal McGlynn's Natus Medical Inc position peaked at $48M in Q3 2019.
  • 159 funds tracked by Wall St. Rank held Natus Medical Inc as of Q3 2020.

Based on Cramer Rosenthal McGlynn's 13F filing for Q3 2020, filed 13 Nov 2020.